Promis Neurosciences inc (PMN) - News Archive

Advancements in Alzheimer s Therapy: ProMIS Neurosciences PMN310 Progresses to Final Dose Escalation in Phase 1b Clinical Trial Alzheimer s disease (AD), the most prevalent form of dementia, continues to be a critical p...

In a monumental stride towards addressing one of the most pressing healthcare challenges of our time, ProMIS Neurosciences has made significant headway with its innovative approach to Alzheimer’s disease and other neuro...

Unlocking Hope: ProMIS Neurosciences’ Strategic Advances in the Fight Against Neurodegenerative Diseases In an era marked by advancing scientific frontiers, ProMIS Neurosciences Inc. has consistently fortified its posit...

ProMIS Neurosciences: Promising Advances in Antibody Therapeutics Amidst Competitive Revenue ChallengesIn a pivotal moment for the field of neurodegenerative disease research, ProMIS Neurosciences has recently showcased...

Neurodegenerative diseases such as Alzheimer s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) pose significant challenges in both clinical treatment and research. As these diseases...

ProMIS Neurosciences Inc. a clinical-stage biotechnology company dedicated to developing antibody therapeutics aimed at toxic misfolded proteins associated with neurodegenerative diseases, is expected to participate in...

In a significant leap forward in the fight against neurodegenerative diseases, ProMIS Neurosciences Inc. (Nasdaq: PMN), a pioneering biotechnology firm, is garnering attention with its innovative approach to targeting t...

CAMBRIDGE, Massachusetts and TORONTO, Ontario, September 5, 2024 - ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotech firm at the cutting edge of the fight against neurodegenerative diseases, has confirmed its participa...

: Recent announcements from ProMIS Neurosciences spotlight a pivotal moment in the ongoing battle against Alzheimer’s disease. With the release of positive topline data from the first-in-human Phase 1a clinical trial of...

Advancements in Neurodegenerative Therapeutics: ProMIS Neurosciences Progress and Upcoming Milestones Neurodegenerative diseases such as Alzheimer s disease represent significant challenges in modern medicine, with high...

In a notable development within the realm of Alzheimer’s disease research, ProMIS Neurosciences has shared pivotal topline results from its Phase 1a clinical trial, involving its innovative therapeutic candidate, PMN310...

In the search for an effective treatment for Alzheimer s disease, ProMIS Neurosciences has emerged as a leading player with their cutting-edge therapeutic candidate, PMN310. The company recently released its first-quart...